K. Kant

发表

Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance.

M. A. Miller, E. Hess, V. Pollak, 1981, Medicine.

Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants.

M. A. Miller, V. Pollak, M. Miller, 1985, Archives of internal medicine.

Targeted knockdown of Kv1.3 channels in T lymphocytes corrects the disease manifestations associated with systemic lupus erythematosus

M. Khodoun, L. Conforti, H. J. Duncan, 2020, Science Advances.

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.

B. Garrett, E. Slatopolsky, A. Bleyer, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Nephritis in systemic lupus erythematosus

V. Pollak, K. Kant, 1981, California medicine.

Multiple use of dialyzers: safety and efficacy.

V. Pollak, K. Kant, D. Goetz, 1981, Kidney international.

Diffuse and focal proliferative lupus nephritis: treatment approaches and results.

S. Hariharan, V. Pollak, K. Kant, 1991, Nephron.

Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.

A. R. González, M. Plone, J. Hertel, 2012, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

Continuous quality improvement in chronic disease: a computerized medical record enables description of a severity index to evaluate outcomes in end-stage renal disease.

A. Pesce, V. Pollak, K. Kant, 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Ancrod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolysis effects.

P. Penovich, V. Pollak, K. Kant, 1984, Archives of internal medicine.

Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.

V. Pollak, K. Kant, P. Glas-Greenwalt, 1985, The Journal of laboratory and clinical medicine.

Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod.

V. Pollak, H. Glueck, K. Kant, 1985, The Journal of laboratory and clinical medicine.

The Application of Enzyme Immunoassay in the Diagnosis of Autoimmune Disease

A. Pesce, A. Pesce, V. Pollak, 1978 .

Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura.

J. Hall, V. Pollak, K. Kant, 1986, The Journal of laboratory and clinical medicine.

Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.

V. Pollak, K. Kant, P. Glas-Greenwalt, 1984, The Journal of laboratory and clinical medicine.

Relapsing Peritonitis in Continuous Ambulatory Peritoneal Dialysis (CAPD): Treatment by Interruption of CAPO and Prolonged Antibiotic Therapy

K. Kant, D. Goetz, Cynthia Marzluff, 1988 .

Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness

J. Lewis, U. Bhatt, S. Fadem, 2015, Therapeutic advances in chronic disease.

Protein S deficiency and skin necrosis associated with continuous ambulatory peritoneal dialysis.

I. Penn, H. Glueck, K. Kant, 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effect of first and subsequent use of hemodialyzers on patient well-being: the rise and fall of a syndrome associated with new dialyzer use.

V. Pollak, K. Kant, M. Robson, 1987, Artificial organs.

INTRADIALMIC CARDlAC ARRHYTHMIAS: II

K. Kant, 1994 .

Steroid withdrawal following HLA-identical related donor transplantation.

J. Alexander, M. First, K. Kant, 1981, Transplantation proceedings.

Successful treatment by defibrination with ancrod in a patient with hyperacute renal allograft failure and a deficiency of plasma prostacyclin stimulating factor.

J. Alexander, M. First, V. Pollak, 1982, Clinical nephrology.

Nephrotoxicity of low molecular weight serum proteins: physicochemical interactions between myoglobin, hemoglobin, bence-jones proteins and tamm-horsfall mucoprotein.

A. Pesce, V. Pollak, K. Kant, 1979, Current problems in clinical biochemistry.

Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

J. Lewis, T. Greene, M. Koury, 2015, Journal of the American Society of Nephrology : JASN.

Henoch-Schönlein purpura in a patient with diabetic nephropathy: case report and a review of the literature.

K. Kant, M. Weiss, B. Padilla, 1992, American Journal of Kidney Diseases.

Pancreatitis in Patients with End‐Stage Renal Disease

J. Deddens, V. Pollak, K. Kant, 1994, Medicine.

Role of C‐reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients

K. Kant, M. El-Khatib, H. Duncan, 2006, Nephrology.

Deficiency of a plasma factor stimulating vascular prostacyclin generation in patients with lupus nephritis and glomerular thrombi and its correction by ancrod: in-vivo and in-vitro observations.

V. Pollak, K. Kant, M. Weiss, 1982, Thrombosis research.

Dialyzer membranes: syndromes associated with first use and effects of multiple use.

V. Pollak, K. Kant, M. Robson, 1988, Kidney international. Supplement.

Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).

V. Pollak, K. Kant, P. Glas-Greenwalt, 1985, Clinical nephrology.

Antiphospholipid antibodies and the kidney.

R. Asherson, K. Kant, 1993, The Journal of rheumatology.

Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants.

K. Kant, M. Coots, H. I. Glueck, 1985, Archives of internal medicine.